Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer

References

• Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640. doi:10.1016/j.mayocp.2019.01.01331378236
   PubMed Web of Science ®Google Scholar
• Wang BY, Huang JY, Cheng CY, Lin CH, Ko J, Liaw YP. Lung cancer and prognosis in Taiwan: a population-based cancer registry. J Thorac Oncol. 2013;8(9):1128–1135. doi:10.1097/JTO.0b013e31829ceba423945383
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.2165433433946
   PubMed Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–774. doi:10.1001/jama.2019.1105831454018
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa160677427718847
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aggarwal C, et al. NCCN guidelines insights: non-small cell lung cancer, Version 1.2020. J Natl Compr Canc Netw. 2019;17(12):1464–1472. doi:10.6004/jnccn.2019.005931805526
   PubMed Web of Science ®Google Scholar
• Shih JY, Inoue A, Cheng R, Varea R, Kim SW. Does pemetrexed work in targetable, nonsquamous non-small-cell lung cancer? A narrative review. Cancers (Basel). 2020;12(9):Sep. doi:10.3390/cancers12092658
   Web of Science ®Google Scholar
• Treat J, Scagliotti GV, Peng G, Monberg MJ, Obasaju CK, Socinski MA. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three Phase 3 trials. Lung Cancer. 2012;76(2):222–227. doi:10.1016/j.lungcan.2011.10.02122115704
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the Phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895–2902. doi:10.1200/JCO.2012.47.110223835707
   PubMed Web of Science ®Google Scholar
• Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer. 2011;74(1):132–138. doi:10.1016/j.lungcan.2011.01.02421367480
   PubMed Web of Science ®Google Scholar
• Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer. 2011;104(10):1594–1601. doi:10.1038/bjc.2011.12921487406
   PubMed Web of Science ®Google Scholar
• Krawczyk P, Kucharczyk T, Kowalski DM, et al. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. J Cancer Res Clin Oncol. 2014;140(12):2047–2057. doi:10.1007/s00432-014-1756-625028118
   PubMed Web of Science ®Google Scholar
• Li WJ, Jiang H, Fang XJ, et al. Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. Oncol Lett. 2013;5(4):1165–1170. doi:10.3892/ol.2013.117523599757
   PubMed Web of Science ®Google Scholar
• Park S, Park TS, Choi CM, et al. Survival benefit of pemetrexed in lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements. Clin Lung Cancer. 2015;16(5):e83–9. doi:10.1016/j.cllc.2015.01.00325682546
   PubMed Web of Science ®Google Scholar
• Wu SG, Yang CH, Yu CJ, et al. Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer. 2011;72(3):333–339. doi:10.1016/j.lungcan.2010.10.01221111508
   PubMed Web of Science ®Google Scholar
• Wu MF, Hsiao YM, Huang CF, et al. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol. 2010;5(8):1143–1151. doi:10.1097/JTO.0b013e3181e0b95420559153
   PubMed Web of Science ®Google Scholar
• Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer. 2015;15(12):712–729. doi:10.1038/nrc402726597527
   PubMed Web of Science ®Google Scholar
• Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumor Biol. 2013;34(4):2041–2051. doi:10.1007/s13277-013-0842-8
   PubMedGoogle Scholar
• Rossi E, Bernabeu C, Smadja DM. Endoglin as an adhesion molecule in mature and progenitor endothelial cells: a function beyond TGF-beta. Front Med (Lausanne). 2019;6:10. doi:10.3389/fmed.2019.0001030761306
   PubMed Web of Science ®Google Scholar
• Vidal AC, Duong F, Howard LE, et al. Soluble endoglin (sCD105) as a novel biomarker for detecting aggressive prostate cancer. Anticancer Res. 2020;40(3):1459–1462. doi:10.21873/anticanres.1408832132043
   PubMed Web of Science ®Google Scholar
• Schwartz LH, Litiere S, de Vries E, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–137. doi:10.1016/j.ejca.2016.03.08127189322
   PubMed Web of Science ®Google Scholar
• Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol Chem. 2012;393(5):301–317. doi:10.1515/hsz-2011-026022505514
   PubMed Web of Science ®Google Scholar
• Schoonderwoerd MJA, Goumans MTH, Hawinkels L. Endoglin: beyond the endothelium. Biomolecules. 2020;10(2):Feb. doi:10.3390/biom10020289
   Web of Science ®Google Scholar
• Tian H, Huang JJ, Golzio C, et al. Endoglin interacts with VEGFR2 to promote angiogenesis. FASEB J. 2018;32(6):2934–2949. doi:10.1096/fj.201700867RR29401587
   PubMed Web of Science ®Google Scholar
• Paauwe M, Heijkants RC, Oudt CH, et al. Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer. Oncogene. 2016;35(31):4069–4079. doi:10.1038/onc.2015.50926804178
   PubMed Web of Science ®Google Scholar
• Apolo AB, Karzai FH, Trepel JB, et al. A Phase II clinical trial of TRC105 (Anti-Endoglin Antibody) in adults with advanced/metastatic urothelial carcinoma. Clin Genitourin Cancer. 2017;15(1):77–85. doi:10.1016/j.clgc.2016.05.01027328856
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Michaelson MD, Posadas EM, et al. An open label Phase Ib dose escalation study of TRC105 (Anti-Endoglin Antibody) with axitinib in patients with metastatic renal cell carcinoma. Oncologist. 2019;24(2):202–210. doi:10.1634/theoncologist.2018-029930190302
   PubMed Web of Science ®Google Scholar
• Davidson B, Stavnes HT, Forsund M, Berner A, Staff AC. CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival. Breast. 2010;19(6):493–498. doi:10.1016/j.breast.2010.05.01321078485
   PubMed Web of Science ®Google Scholar
• Kauer J, Schwartz K, Tandler C, et al. CD105 (Endoglin) as negative prognostic factor in AML. Sci Rep. 2019;9(1):18337. doi:10.1038/s41598-019-54767-x31797971
   PubMed Web of Science ®Google Scholar
• Paauwe M, Schoonderwoerd MJA, Helderman R, et al. Endoglin expression on cancer-associated fibroblasts regulates invasion and stimulates colorectal cancer metastasis. Clin Cancer Res. 2018;24(24):6331–6344. doi:10.1158/1078-0432.CCR-18-032929945992
   PubMed Web of Science ®Google Scholar
• O’Leary K, Shia A, Cavicchioli F, et al. Identification of Endoglin as an epigenetically regulated tumor-suppressor gene in lung cancer. Br J Cancer. 2015;113(6):970–978. doi:10.1038/bjc.2015.30226325105
   PubMed Web of Science ®Google Scholar
• Okamoto I, Aoe K, Kato T, et al. Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naive patients with advanced nonsquamous non-small-cell lung cancer. Invest New Drugs. 2013;31(5):1275–1282. doi:10.1007/s10637-013-9941-z23475281
   PubMed Web of Science ®Google Scholar
• Schuette WH, Groschel A, Sebastian M, et al. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer. 2013;14(3):215–223. doi:10.1016/j.cllc.2012.10.00123332288
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247–255. doi:10.1016/S1470-2045(12)70063-322341744
   PubMed Web of Science ®Google Scholar
• Castonguay R, Werner ED, Matthews RG, et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem. 2011;286(34):30034–30046. doi:10.1074/jbc.M111.26013321737454
   PubMed Web of Science ®Google Scholar
• Jiang X, Yang B, Lu J, Zhan Z, Li K, Ren X. Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes. Tumor Biol. 2015;36(2):861–869. doi:10.1007/s13277-014-2692-4
   PubMedGoogle Scholar